Document Detail

Effect on anterior chamber bevacizumab injection combined with seton implantation in treatment of rubeosis iridis in neovascular glaucoma.
MedLine Citation:
PMID:  21995758     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To evaluate the effect of anti-VEGF (bevacizumab) injection to the posterior chamber (BIPC) behind the iris combined with seton implantation in treatment of neovascular glaucoma (NVG).
METHODS: Twenty-eight eyes with NVG who underwent BIPC, prospectively evaluated. Anterior segment photographs were taken for grading of neovascularization on anterior segment in pretreatment period and at each follow-up. Grading and regression of rubeosis iridis was classified according to Teich and Walsh grading system and glaucoma filtration surgery with drainage device was performed following BIPC.
RESULTS: The mean pre-BIPC IOP was 39.71 ± 7.09 mmHg, post-BIPC IOP in the 1st, 2nd day, 1st week, 1st, 3rd, 6th month were 19.7 ± 8.9 mmHg, 13.5 ± 6.7 mmHg, 9.9 ± 3.4 mmHg, 13.07 ± 5.3 mmHg, 16.6 ± 5.03 mmHg, 18.5 ± 3.8 mmHg, respectively. Twenty seven eyes underwent seton implantation surgery. No one had anterior segment bleeding during surgery. The pre-BIPC grades were Grade 4: 67.58%, Grade 3: 28.57%, Grade 2: 3.57%, no one had Grade 1or Grade 0, while post BIPC grade were at the 1st week Grade 1: 64.28%, Grade 0: 35.71%, no one had Grade 2 or more, at 1st month Grade 2: 3.57%, Grade 1: 39.28%, Grade 0: 57.14%, at 3rd month Grade 2: 17.85% Grade 1: 28.57%, Grade 0: 53.57%, no one had Grade 3 or more both in first and the third month, at 6th month Grade 3: 7.14%, Grade 2: 28.57%, Grade 1: 42.85%, Grade 0: 21.42%. and no one had Grade 4.
CONCLUSION: Significant reduction of NV was observed during the first week. Minimal increasement was seen in third month, significant regression effect persisted for 6 months. BIPC inhibited the peroperative risk of anterior segment bleeding, increased the surgical comfort and prevented the failure of filtration procedure by inhibiting reproliferation.
Ayse Gul Kocak Altintas; Hasan Basri Arifoglu; Esen Tutar; Gultekin Koklu; Pehmen Yasin Ozcan
Related Documents :
1703638 - Venous angioma: follow-up study and therapeutic considerations.
15899958 - Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with in...
14605748 - Low-dose radiotherapy for painful heel spur. retrospective study of 117 patients.
1879218 - The use of corticotropin releasing factor (cre) for the treatment of post-operative cer...
23381198 - Clinical benefits of methylprednisolone in off-pump coronary artery bypass surgery.
25027768 - Short- and long-term efficacy of cholinesterase inhibitors in older adults with alzheim...
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2011-10-13
Journal Detail:
Title:  Cutaneous and ocular toxicology     Volume:  31     ISSN:  1556-9535     ISO Abbreviation:  Cutan Ocul Toxicol     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-05-17     Completed Date:  2012-09-18     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  101266892     Medline TA:  Cutan Ocul Toxicol     Country:  England    
Other Details:
Languages:  eng     Pagination:  124-7     Citation Subset:  IM    
S.B. Ulucanlar Eye Research and Education Hospital, Ophthalmology Department, Ankara, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / administration & dosage*
Anterior Chamber
Antibodies, Monoclonal, Humanized / administration & dosage*
Glaucoma, Neovascular / drug therapy*
Iritis / drug therapy
Middle Aged
Suture Techniques
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Secondary postpartum hemorrhage due to uterine artery pseudoaneurysm rupture in von Willebrand disea...
Next Document:  Assessment of home environments with a fungal index using hydrophilic and xerophilic fungi as biolog...